Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NEB PET Imaging in Lymphatic Disorders
NCT04273334Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2019
- Primary completion
- Dec 2022
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial of 68Ga-NOTA-Evans Blue in Lymphatic disorder, lymphedema, lymphangioma and 3 more, sponsored by Peking Union Medical College Hospital. Primary endpoint: Standardized uptake value at 1 year. Status: unknown.
02
Drugs
68Ga-NOTA-Evans Blue
03
Conditions
Lymphatic disorderlymphedemalymphangiomalymphangioleiomyomatosis (LAM)plastic bronchitis (PB)
Beyond the preview
Go deeper on NCT04273334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04273334.